This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Bayer (BAYRY) Q2 Earnings In Line, Nubeqa, Kerendia Boost Sales
by Zacks Equity Research
Bayer's (BAYRY) second-quarter earnings match the consensus estimate. Sales gain from the Pharmaceutical business' strong performance.
Intuitive Surgical (ISRG) Rises 5% Post Earnings: What's Next?
by Indrajit Bandyopadhyay
Intuitive Surgical (ISRG) is making strides in the robotic-assisted surgery market with its existing and new launches. However, macro challenges are likely to continue to hurt its performance.
The Market's Excessive Recession Fears
by Sheraz Mian
We comment on the ongoing market sell-off, in addition to featuring new research reports on Johnson & Johnson (JNJ), T-Mobile (TMUS) and Marsh & McLennan (MMC) and others.
TEVA Q2 Earnings Beat, Generic Business Drives Sales, Stock Up
by Zacks Equity Research
TEVA reports better-than-expected second-quarter results, beating both earnings and sales estimates. Management raises the 2024 financial outlook. The stock climbs 6.2% in response.
GSK Beats Q2 Earnings & Sales Estimates, Ups 2024 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across the Specialty Medicines and General Medicines segments. It raises guidance for earnings and sales for the full year.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?
by Kinjel Shah
Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.
AbbVie (ABBV) Beats on Q2 Earnings & Sales, Ups '24 EPS View
by Zacks Equity Research
AbbVie's (ABBV) second-quarter earnings and sales beat estimates. Management hikes the EPS guidance on encouraging product sales for immunology drugs.
GSK Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
We expect GSK's specialty products like Arexvy, Cabenuva, Juluca, Dovato, Trelegy Ellipta and Shingrix to drive second-quarter sales performance.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Time for Healthcare ETFs?
by Sanghamitra Saha
Compelling valuation, innovation in specific growth areas and an aging population as well as increasing healthcare spending are the tailwinds of the medical sector.
GSK Blenrep Combos for Multiple Myeloma Accepted for EU Review
by Zacks Equity Research
GSK announces the acceptance of its regulatory filing, seeking the approval of Blenrep combinations for the treatment of relapsed or refractory multiple myeloma, for review in the EU.
AbbVie (ABBV) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Investor focus will likely be on sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports second-quarter results.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, RHHBY's Positive Obesity Pill Data
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) beat estimates for earnings and sales. Roche's (RHHBY) oral weight loss GLP-1 therapy achieves positive results in an early-stage study.
Company News for Jul 18, 2024
by Zacks Equity Research
Companies in The News Are: JNJ,SYF,CFG,FHN
J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs
by Kinjel Shah
J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.
ORIC Pharmaceuticals (ORIC) Up on Collaboration With Bayer & JNJ
by Zacks Equity Research
ORIC Pharmaceuticals (ORIC) teams up with Bayer and Johnson & Johnson for a phase I study on ORIC-944 in patients with metastatic prostate cancer. Its shares rise on the news.
Housing Starts Increased More Than Expected
by Zacks Equity Research
Housing Starts Increased More Than Expected
Pre-Markets Book Profits; Housing Starts, J&J Q2 Up
by Mark Vickery
Pre-market futures are down at this hour, but not apparently as a result of any new reports ahead of the bell.
Johnson & Johnson (JNJ) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Johnson & Johnson (JNJ) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Johnson & Johnson (JNJ) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Johnson & Johnson (JNJ) delivered earnings and revenue surprises of 4.06% and 0.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Stock Market News for Jul 16, 2024
by Zacks Equity Research
U.S stocks closed higher on Monday, building on Friday???s rally, as investors increased their bets on the chances of Donald Trump winning the U.S. presidential election in November following a failed assassination attempt on the Republican nominee over the weekend.